4D Molecular Therapeutics (FDMT)

• Market cap: $518M
• 1 day: 10.48%
• 5 days: 14.17%
• 1 month: 12.49%
• 3 months: 6.22%
• 6 months: -5.71%
• Year to date: 35.38%
• 1 year: 167.12%
• 5 years: -63.59%
• 10 years: -75.53%
• Sector: Healthcare
• Industry: Biotechnology

About: 4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).

Employees: 196